MRZM Stock Overview
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Marizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.095 |
| 52 Week High | US$0.41 |
| 52 Week Low | US$0.05 |
| Beta | 0.17 |
| 1 Month Change | 0% |
| 3 Month Change | -5.09% |
| 1 Year Change | -26.58% |
| 3 Year Change | -95.58% |
| 5 Year Change | -93.67% |
| Change since IPO | -94.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRZM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | -26.6% | 0.9% | 21.9% |
Return vs Industry: MRZM underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: MRZM underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| MRZM volatility | |
|---|---|
| MRZM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRZM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MRZM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | David Barthel | www.marizyme.com |
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It’s product portfolio includes DuraGraft, a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure; MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that provides a therapeutics opportunity for wound healing, thrombosis, and pet health. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. Fundamentals Summary
| MRZM fundamental statistics | |
|---|---|
| Market cap | US$4.43m |
| Earnings (TTM) | -US$79.15m |
| Revenue (TTM) | US$590.91k |
7.5x
P/S Ratio-0.1x
P/E RatioIs MRZM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRZM income statement (TTM) | |
|---|---|
| Revenue | US$590.91k |
| Cost of Revenue | US$378.93k |
| Gross Profit | US$211.98k |
| Other Expenses | US$79.36m |
| Earnings | -US$79.15m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 35.87% |
| Net Profit Margin | -13,393.81% |
| Debt/Equity Ratio | -92.9% |
How did MRZM perform over the long term?
See historical performance and comparison